Valuation: Mercury Laboratories Limited

Market Cap 840M 8.8M 7.65M 7.12M 6.54M 12.34M 12.54M 83.93M 32.94M 418M 33.05M 32.32M 1.4B P/E 2024
17.7x
P/E 2025 31.3x
Enterprise Value 879M 9.21M 8M 7.45M 6.84M 12.92M 13.12M 87.82M 34.47M 438M 34.58M 33.82M 1.47B EV / Sales 2024
1.29x
EV / Sales 2025 1.36x
Free-Float
13.68%
Yield 2024
0.42%
Yield 2025 0.43%
07-25 Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-11 Mercury Laboratories Limited Announces Appointment of Binaya Kumar Panigrahi as Plant Head (Jarod Unit), Effective June 11, 2026 CI
05-29 Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
05-29 Mercury Laboratories Limited Recommends Dividend for the Financial Year Ended March 31, 2026 CI
05-29 Mercury Laboratories recommends final dividend of 3.50 rupees per share RE
04-29 Mercury Laboratories Limited Announces Resignation of Sandip Patel as Plant Head-Jarod, Effective April 28, 2026 CI
02-11 Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-11 Mercury Laboratories to establish SVP plant at 300 million rupees RE
11-11 Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-07 Mercury Laboratories Limited Announces Resignation of Mukesh Shrivastava as Vice President Marketing & Sales Designated as Senior Management Personnel, Effective from November 07, 2025 CI
11-04 Mercury Laboratories Limited Announces Appointment of Seema Salvi as Head of the Department (Dept.-Injectable Production), Effective November 04, 2025 CI
25-08-14 Mercury Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2025 CI
25-08-13 Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
1 week-4.67%
1 month+0.76%
3 months+6.13%
6 months+1.40%
Current year-1.87%
1 week 783
Extreme 783
826
1 month 767
Extreme 767
901.9
Current year 620.55
Extreme 620.55
928.5
1 year 620.55
Extreme 620.55
976
3 years 620.55
Extreme 620.55
1,303
5 years 390
Extreme 390
1,303
10 years 212
Extreme 212
1,303
Manager TitleAgeSince
Chief Executive Officer 74 1982-02-15
Director of Finance/CFO 54 2021-10-20
Chief Operating Officer 41 2023-11-07
Director TitleAgeSince
Chairman 74 2015-02-22
Director/Board Member 71 1982-02-15
Director/Board Member 57 2017-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-4.67%-8.35%-0.30% 10.01M
+0.32%-0.66%+64.21%+23.67% 322B
+0.21%+2.87%+33.60%-10.34% 71.6B
-0.91%+0.74%+39.85%+95.22% 9.79B
-3.60%-2.43%-1.16%-6.92% 8.39B
+1.80%-1.99%-15.78%-12.22% 4.3B
-0.68%-1.87%-34.78%+3.04% 3.81B
+3.08%-1.41%-12.94%+9.52% 3.58B
-2.15%-3.40%+25.70%+40.83% 2.59B
+0.85%+9.88%-0.25%-7.32% 2.25B
Average -0.11%-0.77%+9.01%+13.52% 42.79B
Weighted average by Cap. +0.21%-0.09%+54.34%+18.29%

Financials

2024 2025
Net sales 756M 7.92M 6.88M 6.4M 5.88M 11.1M 11.28M 75.49M 29.63M 376M 29.73M 29.07M 1.26B 751M 7.87M 6.84M 6.37M 5.84M 11.04M 11.21M 75.03M 29.45M 374M 29.55M 28.9M 1.25B
Net income 56.54M 592K 515K 479K 440K 831K 844K 5.65M 2.22M 28.15M 2.22M 2.18M 94.39M 31.45M 329K 286K 267K 245K 462K 469K 3.14M 1.23M 15.66M 1.24M 1.21M 52.5M
Net Debt -25.4M -266K -231K -215K -198K -373K -379K -2.54M -996K -12.65M -999K -977K -42.4M 38.95M 408K 355K 330K 303K 572K 581K 3.89M 1.53M 19.39M 1.53M 1.5M 65.01M
Logo Mercury Laboratories Limited
Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. It is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, and innovative products. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.
Employees
503
Date Price Change Volume
26-07-31 ₹796.00 -.--% 4
26-07-30 ₹796.00 +1.23% 3
26-07-29 ₹786.30 -1.84% 75
26-07-28 ₹801.00 -0.08% 9
26-07-27 ₹801.65 -3.99% 401
  1. Stock Market
  2. Stocks
  3. MERCURYLAB6 Stock